We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
UTMD Trades at a Premium to the Industry: How to Play the Stock?
Read MoreHide Full Article
From a valuation perspective, Utah Medical Products, Inc. (UTMD - Free Report) stock looks expensive. UTMD is currently trading at a trailing 12-month enterprise value/sales (EV/sales) of 4.05X, above the industry average of 2.68X. UTMD also trades at a higher valuation compared to other industry players, such as Evolus, Inc. (EOLS - Free Report) and Canopy Growth Corporation (CGC - Free Report) . Currently, EOLS and CGC trade at EV/sales multiples of 1.97X and 1.41X, respectively.
Image Source: Zacks Investment Research
While this elevated valuation reflects investor confidence in the company’s long-term potential, it also raises concerns about whether the stock can justify such lofty multiple. Considering the premium valuation, investors must be wondering whether they should buy, hold or sell the stock.
UTMD Stock’s Price Performance
Utah Medical’s shares have gained 16.7% in the past year against the industry’s 30.1% decline. The Zacks Medical sector has risen 4.1% while the S&P 500 has advanced 18%. Meanwhile, UTMD has outperformed CGC’s 46.9% decline but underperformed Evolus’ 24.2% rally in the same time frame.
Image Source: Zacks Investment Research
Business Tailwinds for UTMD
Utah Medical’s wholly owned subsidiary, Femcare Ltd., acquired Orion Medical Supplies in August 2026, providing an opportunity to expand its revenue base and improve operating efficiency. The acquired business is expected to contribute approximately $6 million in annual sales, supported by established demand for harm-reduction medical devices in the U.K. and Europe. Integrating Orion into Femcare’s existing infrastructure should improve overhead absorption, while opportunities for geographic expansion could support long-term growth.
UTMD’s strong financial position provides flexibility to pursue growth initiatives and shareholder returns. Cash and investments increased to $87.5 million as of June 30, 2026, from $85.8 million as of Dec. 31, 2025, while the company remained debt-free. Operating activities generated $4.5 million in cash during the first half of 2026. Its substantial liquidity supports investments in new technologies, potential acquisitions and product development without significant dependence on external financing.
UTMD continues to demonstrate resilient profitability despite softer revenues. Gross margin improved to 58.2% in the first half of 2026 from 56.6% in the year-ago period, reflecting a more favorable product mix and the absence of lower-margin sales to its former Chinese distributor. Operating margin remained healthy at 30.2%, while net margin stood at 30.7%. Its ability to sustain strong margins amid sales pressure highlights the underlying profitability of its specialized medical-device portfolio.
UTMD’s product development initiatives and expanding biopharmaceutical customer base offer additional growth opportunities. Sales to domestic OEM customers excluding PendoTECH increased by $0.2 million in the first half of 2026, including $0.07 million from new biopharmaceutical customers. Management is targeting additional sales of high-pressure process-control transducer configurations to biopharmaceutical manufacturers. New product introductions and broader customer relationships could gradually offset lost business.
UTMD’s consistent shareholder distributions reflect its cash-generating capabilities and disciplined capital allocation. In August 2026, the company announced a quarterly dividend of 31 cents per share, representing a 1.6% year-over-year increase. During the first half of 2026, UTMD distributed approximately $2 million in dividends and repurchased $0.2 million of common stock. Its substantial cash reserves and continued commitment to opportunistic buybacks support shareholder returns alongside future investments.
Headwinds for UTMD’s Business
Utah Medical’s revenues fell 12.3% to $17.3 million in the first half of 2026, primarily due to discontinued sales to two major customers. Slower-than-expected demand from new biopharma customers has further constrained recovery, prompting management to project a 10-13% revenue decline for 2026. Lower production volumes and elevated manufacturing overhead pressured profitability, with operating income declining 17.9% to $5.2 million. Filshie Clip System tariffs and rising raw material prices added cost pressures, while litigation expenses increased $0.3 million year over year.
Conclusion
UTMD’s strong balance sheet, healthy margins, strategic acquisition and product development initiatives support its long-term growth prospects. However, near-term revenue pressures, customer losses and rising costs warrant caution.
Also, its valuation is higher than the industry average. For long-term investors, UTMD’s strong fundamentals may justify holding the stock, but investors looking to add the stock to their portfolios may want to wait for a better entry point.
View the Zacks #1 Rank List
Image: Bigstock
UTMD Trades at a Premium to the Industry: How to Play the Stock?
From a valuation perspective, Utah Medical Products, Inc. (UTMD - Free Report) stock looks expensive. UTMD is currently trading at a trailing 12-month enterprise value/sales (EV/sales) of 4.05X, above the industry average of 2.68X. UTMD also trades at a higher valuation compared to other industry players, such as Evolus, Inc. (EOLS - Free Report) and Canopy Growth Corporation (CGC - Free Report) . Currently, EOLS and CGC trade at EV/sales multiples of 1.97X and 1.41X, respectively.
Image Source: Zacks Investment Research
While this elevated valuation reflects investor confidence in the company’s long-term potential, it also raises concerns about whether the stock can justify such lofty multiple. Considering the premium valuation, investors must be wondering whether they should buy, hold or sell the stock.
UTMD Stock’s Price Performance
Utah Medical’s shares have gained 16.7% in the past year against the industry’s 30.1% decline. The Zacks Medical sector has risen 4.1% while the S&P 500 has advanced 18%. Meanwhile, UTMD has outperformed CGC’s 46.9% decline but underperformed Evolus’ 24.2% rally in the same time frame.
Image Source: Zacks Investment Research
Business Tailwinds for UTMD
Utah Medical’s wholly owned subsidiary, Femcare Ltd., acquired Orion Medical Supplies in August 2026, providing an opportunity to expand its revenue base and improve operating efficiency. The acquired business is expected to contribute approximately $6 million in annual sales, supported by established demand for harm-reduction medical devices in the U.K. and Europe. Integrating Orion into Femcare’s existing infrastructure should improve overhead absorption, while opportunities for geographic expansion could support long-term growth.
UTMD’s strong financial position provides flexibility to pursue growth initiatives and shareholder returns. Cash and investments increased to $87.5 million as of June 30, 2026, from $85.8 million as of Dec. 31, 2025, while the company remained debt-free. Operating activities generated $4.5 million in cash during the first half of 2026. Its substantial liquidity supports investments in new technologies, potential acquisitions and product development without significant dependence on external financing.
UTMD continues to demonstrate resilient profitability despite softer revenues. Gross margin improved to 58.2% in the first half of 2026 from 56.6% in the year-ago period, reflecting a more favorable product mix and the absence of lower-margin sales to its former Chinese distributor. Operating margin remained healthy at 30.2%, while net margin stood at 30.7%. Its ability to sustain strong margins amid sales pressure highlights the underlying profitability of its specialized medical-device portfolio.
UTMD’s product development initiatives and expanding biopharmaceutical customer base offer additional growth opportunities. Sales to domestic OEM customers excluding PendoTECH increased by $0.2 million in the first half of 2026, including $0.07 million from new biopharmaceutical customers. Management is targeting additional sales of high-pressure process-control transducer configurations to biopharmaceutical manufacturers. New product introductions and broader customer relationships could gradually offset lost business.
UTMD’s consistent shareholder distributions reflect its cash-generating capabilities and disciplined capital allocation. In August 2026, the company announced a quarterly dividend of 31 cents per share, representing a 1.6% year-over-year increase. During the first half of 2026, UTMD distributed approximately $2 million in dividends and repurchased $0.2 million of common stock. Its substantial cash reserves and continued commitment to opportunistic buybacks support shareholder returns alongside future investments.
Headwinds for UTMD’s Business
Utah Medical’s revenues fell 12.3% to $17.3 million in the first half of 2026, primarily due to discontinued sales to two major customers. Slower-than-expected demand from new biopharma customers has further constrained recovery, prompting management to project a 10-13% revenue decline for 2026. Lower production volumes and elevated manufacturing overhead pressured profitability, with operating income declining 17.9% to $5.2 million. Filshie Clip System tariffs and rising raw material prices added cost pressures, while litigation expenses increased $0.3 million year over year.
Conclusion
UTMD’s strong balance sheet, healthy margins, strategic acquisition and product development initiatives support its long-term growth prospects. However, near-term revenue pressures, customer losses and rising costs warrant caution.
Also, its valuation is higher than the industry average. For long-term investors, UTMD’s strong fundamentals may justify holding the stock, but investors looking to add the stock to their portfolios may want to wait for a better entry point.